Loading...
Apellis Pharmaceuticals, Inc.
APLS•NASDAQ
Healthcare
Biotechnology
$19.59
$-0.50(-2.49%)
Apellis Pharmaceuticals, Inc. (APLS) Financial Performance & Income Statement Overview
Review Apellis Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
97.02%
↑ 97.02%
Operating Income Growth
68.10%
↑ 68.10%
Net Income Growth
62.57%
↑ 62.57%
Operating Cash Flow Growth
85.23%
↑ 85.23%
Operating Margin
-24.00%
↓ 24.002%
Gross Margin
82.94%
↑ 82.94%
Net Profit Margin
-28.83%
↓ 28.83%
ROE
-100.06%
↓ 100.06%
ROIC
-29.61%
↓ 29.61%
Apellis Pharmaceuticals, Inc. (APLS) Income Statement & Financial Overview
Review Apellis Pharmaceuticals, Inc.'s (APLS) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $212.53M | $196.83M | $199.69M | $172.32M |
| Cost of Revenue | $40.86M | $33.56M | $23.55M | $20.65M |
| Gross Profit | $171.67M | $163.27M | $176.14M | $151.67M |
| Gross Profit Ratio | $0.81 | $0.83 | $0.88 | $0.88 |
| R&D Expenses | $76.35M | $88.57M | $77.95M | $84.70M |
| SG&A Expenses | $121.48M | $121.98M | $127.63M | $129.06M |
| Operating Expenses | $197.84M | $210.55M | $205.58M | $213.76M |
| Total Costs & Expenses | $238.69M | $244.11M | $229.13M | $234.41M |
| Interest Income | $3.40M | $2.89M | $3.18M | $3.30M |
| Interest Expense | $11.53M | $12.53M | $9.36M | $6.97M |
| Depreciation & Amortization | $447000.00 | $621000.00 | $449000.00 | $444000.00 |
| EBITDA | -$24.09M | -$43.86M | -$27.73M | -$58.84M |
| EBITDA Ratio | -$0.11 | -$0.22 | -$0.14 | -$0.34 |
| Operating Income | -$26.16M | -$47.28M | -$29.44M | -$62.09M |
| Operating Income Ratio | -$0.12 | -$0.24 | -$0.15 | -$0.36 |
| Other Income/Expenses (Net) | -$9.90M | -$9.57M | -$8.10M | -$4.16M |
| Income Before Tax | -$36.07M | -$56.85M | -$37.54M | -$66.25M |
| Income Before Tax Ratio | -$0.17 | -$0.29 | -$0.19 | -$0.38 |
| Income Tax Expense | $286000.00 | $592000.00 | $114000.00 | $170000.00 |
| Net Income | -$36.35M | -$57.45M | -$37.66M | -$66.42M |
| Net Income Ratio | -$0.17 | -$0.29 | -$0.19 | -$0.39 |
| EPS | -$0.29 | -$0.46 | -$0.30 | -$0.54 |
| Diluted EPS | -$0.29 | -$0.46 | -$0.30 | -$0.54 |
| Weighted Avg Shares Outstanding | $123.90M | $123.90M | $123.90M | $122.96M |
| Weighted Avg Shares Outstanding (Diluted) | $123.90M | $123.90M | $123.90M | $122.96M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan